Elevance Health Q1 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ELV?
Source: seekingalpha
- Strong Earnings Performance: Elevance Health reported a Q1 non-GAAP EPS of $12.58, beating expectations by $1.77, indicating sustained improvement in profitability driven by robust performance in its Health Benefits segment.
- Stable Revenue Growth: The company achieved $49.5 billion in revenue for Q1, a 1.4% year-over-year increase that exceeded market expectations by $1.52 billion, primarily due to higher premium yields and growth in CarelonRx product revenue, despite declines in Medicare and Medicaid membership.
- Effective Cost Management: The operating expense ratio stood at 12.8%, including a $935 million accrual for potential risk exposure; however, the adjusted operating expense ratio decreased to 10.5%, showcasing effective cost management and a focus on long-term growth.
- Optimistic Guidance Outlook: FY 2026 diluted EPS guidance was raised to at least $26.75, surpassing the consensus of $25.75, reflecting the company's proactive measures in reducing medical costs and enhancing business visibility, which are expected to further drive shareholder value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELV
Wall Street analysts forecast ELV stock price to rise
15 Analyst Rating
11 Buy
4 Hold
0 Sell
Moderate Buy
Current: 319.360
Low
332.00
Averages
389.07
High
425.00
Current: 319.360
Low
332.00
Averages
389.07
High
425.00
About ELV
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elevance Health to Announce Q1 Earnings on April 22
- Earnings Announcement Date: Elevance Health (ELV) is set to announce its Q1 earnings on April 22 before market open, with a consensus EPS estimate of $10.77, reflecting a 10.0% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations Decline: The consensus revenue estimate stands at $48.15 billion, down 1.3% year-over-year, indicating challenges the company faces in the current economic environment, potentially affecting its future market performance.
- Historical Performance Review: Over the past two years, Elevance Health has beaten EPS estimates 63% of the time and revenue estimates 88% of the time, demonstrating a degree of stability in financial performance that may attract investor interest.
- Estimates Revision Dynamics: In the last three months, EPS estimates have seen 10 upward revisions and 4 downward revisions, while revenue estimates have experienced 1 upward revision and 6 downward revisions, indicating a divergence in analysts' outlook on the company's future performance, which could influence stock price volatility.
See More
Elevance Health Raises Annual Earnings Outlook
- Earnings Guidance Increase: Elevance Health has raised its fiscal 2026 net income outlook to at least $19.85 per share, reflecting increased confidence in future performance, which is expected to enhance shareholder returns and market trust.
- Adjusted Profit Forecast: The company now anticipates an adjusted profit of at least $26.75 per share for fiscal 2026, supported by strong underlying business performance and measures to reduce medical costs, demonstrating its competitive position in the industry.
- Previous Projections Comparison: Previously, Elevance Health projected a net income of at least $22.30 per share and an adjusted income of at least $25.50 per share for fiscal 2026, with this upward revision indicating positive progress in financial management.
- Dividend Payment Plan: The board has decided to pay a second-quarter dividend of $1.72 per share on June 25 to shareholders of record as of June 10, further strengthening investor confidence and the company's commitment to its shareholders.
See More
Elevance Health Q1 Earnings Exceed Expectations
- Strong Earnings Performance: Elevance Health reported a Q1 non-GAAP EPS of $12.58, beating expectations by $1.77, indicating sustained improvement in profitability driven by robust performance in its Health Benefits segment.
- Stable Revenue Growth: The company achieved $49.5 billion in revenue for Q1, a 1.4% year-over-year increase that exceeded market expectations by $1.52 billion, primarily due to higher premium yields and growth in CarelonRx product revenue, despite declines in Medicare and Medicaid membership.
- Effective Cost Management: The operating expense ratio stood at 12.8%, including a $935 million accrual for potential risk exposure; however, the adjusted operating expense ratio decreased to 10.5%, showcasing effective cost management and a focus on long-term growth.
- Optimistic Guidance Outlook: FY 2026 diluted EPS guidance was raised to at least $26.75, surpassing the consensus of $25.75, reflecting the company's proactive measures in reducing medical costs and enhancing business visibility, which are expected to further drive shareholder value.
See More
Molina Healthcare Shares Rise Following UnitedHealth's Strong Earnings
- Industry Confidence Boost: Molina Healthcare's shares rose 1.9% in the afternoon session as UnitedHealth Group reported stronger-than-expected first-quarter profits, reflecting a surge in investor confidence across the healthcare insurance sector.
- Volatility Insights: The stock has experienced 19 moves greater than 5% over the past year, indicating that today's increase is seen as significant by the market, although it does not fundamentally alter perceptions of Molina's business.
- Profitability Challenges: Molina's adjusted earnings of $1.84 per share fell 52.7% short of analyst expectations of $3.89, prompting the company to lower its 2025 adjusted earnings guidance by 26.3%, highlighting ongoing profitability issues.
- Long-term Investment Returns: Molina's stock is down 15.3% year-to-date, trading at $151.08, which is 54.5% below its 52-week high of $332, indicating that investors who bought $1,000 worth of shares five years ago would now see only $593.78.
See More
US Stocks Rise on Strong Retail Sales and Earnings Reports
- Strong Retail Sales: US March retail sales rose 1.7% month-over-month, exceeding expectations of 1.4% and marking the largest increase in a year, indicating robust consumer spending that could bolster economic recovery and market confidence.
- Earnings Support: UnitedHealth Group (UNH) reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, raising its full-year forecast to above $18.25, which has driven health insurance stocks higher and reflects industry resilience.
- Fed Nomination in Focus: Kevin Warsh's confirmation hearing before the Senate Banking Committee is drawing attention; despite facing an investigation hurdle, Warsh's commitment to an independent Fed and prioritizing inflation control could influence future monetary policy directions.
- International Tensions Impact Oil Prices: WTI crude oil prices fell over 1% as Iran is set to attend peace talks with the US, while the closure of the Strait of Hormuz threatens to exacerbate the global energy crisis, affecting market sentiment.
See More
U.S. Stocks Mixed as Oil Prices Rebound
- Market Performance: The S&P 500 Index fell by 0.13%, and the Dow Jones Industrial Average also declined by 0.13%, while the Nasdaq 100 saw a slight increase of 0.02%, reflecting market volatility influenced by oil price rebounds and economic data.
- Strong Economic Data: March retail sales rose by 1.7% month-over-month, exceeding expectations of 1.4%, marking the largest increase in a year, indicating robust consumer spending that may support stock prices.
- Oil Price Recovery: WTI crude oil prices rebounded by over 2% as market speculation intensified regarding Iran's participation in upcoming peace talks, potentially exacerbating the global energy crisis.
- Impressive Earnings Reports: UnitedHealth Group reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, leading to a stock price increase of over 7% and raising its full-year earnings forecast, showcasing strong performance in the health insurance sector.
See More
Elevance Health to Announce Q1 Earnings on April 22
- Earnings Announcement Date: Elevance Health (ELV) is set to announce its Q1 earnings on April 22 before market open, with a consensus EPS estimate of $10.77, reflecting a 10.0% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations Decline: The consensus revenue estimate stands at $48.15 billion, down 1.3% year-over-year, indicating challenges the company faces in the current economic environment, potentially affecting its future market performance.
- Historical Performance Review: Over the past two years, Elevance Health has beaten EPS estimates 63% of the time and revenue estimates 88% of the time, demonstrating a degree of stability in financial performance that may attract investor interest.
- Estimates Revision Dynamics: In the last three months, EPS estimates have seen 10 upward revisions and 4 downward revisions, while revenue estimates have experienced 1 upward revision and 6 downward revisions, indicating a divergence in analysts' outlook on the company's future performance, which could influence stock price volatility.
See More
Elevance Health Raises Annual Earnings Outlook
- Earnings Guidance Increase: Elevance Health has raised its fiscal 2026 net income outlook to at least $19.85 per share, reflecting increased confidence in future performance, which is expected to enhance shareholder returns and market trust.
- Adjusted Profit Forecast: The company now anticipates an adjusted profit of at least $26.75 per share for fiscal 2026, supported by strong underlying business performance and measures to reduce medical costs, demonstrating its competitive position in the industry.
- Previous Projections Comparison: Previously, Elevance Health projected a net income of at least $22.30 per share and an adjusted income of at least $25.50 per share for fiscal 2026, with this upward revision indicating positive progress in financial management.
- Dividend Payment Plan: The board has decided to pay a second-quarter dividend of $1.72 per share on June 25 to shareholders of record as of June 10, further strengthening investor confidence and the company's commitment to its shareholders.
See More
Elevance Health Q1 Earnings Exceed Expectations
- Strong Earnings Performance: Elevance Health reported a Q1 non-GAAP EPS of $12.58, beating expectations by $1.77, indicating sustained improvement in profitability driven by robust performance in its Health Benefits segment.
- Stable Revenue Growth: The company achieved $49.5 billion in revenue for Q1, a 1.4% year-over-year increase that exceeded market expectations by $1.52 billion, primarily due to higher premium yields and growth in CarelonRx product revenue, despite declines in Medicare and Medicaid membership.
- Effective Cost Management: The operating expense ratio stood at 12.8%, including a $935 million accrual for potential risk exposure; however, the adjusted operating expense ratio decreased to 10.5%, showcasing effective cost management and a focus on long-term growth.
- Optimistic Guidance Outlook: FY 2026 diluted EPS guidance was raised to at least $26.75, surpassing the consensus of $25.75, reflecting the company's proactive measures in reducing medical costs and enhancing business visibility, which are expected to further drive shareholder value.
See More
Molina Healthcare Shares Rise Following UnitedHealth's Strong Earnings
- Industry Confidence Boost: Molina Healthcare's shares rose 1.9% in the afternoon session as UnitedHealth Group reported stronger-than-expected first-quarter profits, reflecting a surge in investor confidence across the healthcare insurance sector.
- Volatility Insights: The stock has experienced 19 moves greater than 5% over the past year, indicating that today's increase is seen as significant by the market, although it does not fundamentally alter perceptions of Molina's business.
- Profitability Challenges: Molina's adjusted earnings of $1.84 per share fell 52.7% short of analyst expectations of $3.89, prompting the company to lower its 2025 adjusted earnings guidance by 26.3%, highlighting ongoing profitability issues.
- Long-term Investment Returns: Molina's stock is down 15.3% year-to-date, trading at $151.08, which is 54.5% below its 52-week high of $332, indicating that investors who bought $1,000 worth of shares five years ago would now see only $593.78.
See More
US Stocks Rise on Strong Retail Sales and Earnings Reports
- Strong Retail Sales: US March retail sales rose 1.7% month-over-month, exceeding expectations of 1.4% and marking the largest increase in a year, indicating robust consumer spending that could bolster economic recovery and market confidence.
- Earnings Support: UnitedHealth Group (UNH) reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, raising its full-year forecast to above $18.25, which has driven health insurance stocks higher and reflects industry resilience.
- Fed Nomination in Focus: Kevin Warsh's confirmation hearing before the Senate Banking Committee is drawing attention; despite facing an investigation hurdle, Warsh's commitment to an independent Fed and prioritizing inflation control could influence future monetary policy directions.
- International Tensions Impact Oil Prices: WTI crude oil prices fell over 1% as Iran is set to attend peace talks with the US, while the closure of the Strait of Hormuz threatens to exacerbate the global energy crisis, affecting market sentiment.
See More
U.S. Stocks Mixed as Oil Prices Rebound
- Market Performance: The S&P 500 Index fell by 0.13%, and the Dow Jones Industrial Average also declined by 0.13%, while the Nasdaq 100 saw a slight increase of 0.02%, reflecting market volatility influenced by oil price rebounds and economic data.
- Strong Economic Data: March retail sales rose by 1.7% month-over-month, exceeding expectations of 1.4%, marking the largest increase in a year, indicating robust consumer spending that may support stock prices.
- Oil Price Recovery: WTI crude oil prices rebounded by over 2% as market speculation intensified regarding Iran's participation in upcoming peace talks, potentially exacerbating the global energy crisis.
- Impressive Earnings Reports: UnitedHealth Group reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, leading to a stock price increase of over 7% and raising its full-year earnings forecast, showcasing strong performance in the health insurance sector.
See More
